Sutro Biopharma STRO Operating Lease Liabilities (Current)
Operating Lease Liabilities (Current) at other companies
Other financials
Where this comes from
Reported directly by Sutro Biopharma in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityCurrent.
The official record: Sutro Biopharma’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Sutro Biopharma's operating lease liabilities (current).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Sutro Biopharma's operating lease liabilities (current)?
- Sutro Biopharma (STRO) reported operating lease liabilities (current) of $7.6M in Q1 2026.
- How has Sutro Biopharma's operating lease liabilities (current) changed year-over-year?
- Sutro Biopharma's operating lease liabilities (current) decreased by 2.1% year-over-year, from $7.77M to $7.6M.
- What is the long-term trend for Sutro Biopharma's operating lease liabilities (current)?
- Over 5 years (2020 to 2025), Sutro Biopharma's operating lease liabilities (current) has grown at a 21.8% compound annual growth rate (CAGR), from $2.9M to $7.78M.
- What does operating lease liabilities (current) mean?
- The current portion of operating lease obligations due within one year, representing committed future lease payments under ASC 842.